Personalis Inc
PSNL5.515USD
+0.125+2.32%
交易中 （美東）報價延遲15分鐘
487.08M總市值
虧損本益比TTM
關於 Personalis Inc 公司
Personalis, Inc. 致力於開發和營銷先進的癌症基因組測試和分析。該公司先進的基因組測序和分析支持個性化癌症疫苗和其他下一代癌症免疫療法的開發。其產品包括 NeXT Personal、ImmunoI DNeXT、NeXT Personal Dx、NeXT Dx、全外顯子組測序 (WES) 和全基因組測序 (WGS)。NeXT Personal 是一種腫瘤知情液體活檢測試，用於檢測癌症中的微小殘留病 (MRD) 和復發。NeXT Dx 是一種全面的腫瘤分析測試，可通過匹配的腫瘤正常分析解鎖整個外顯子組 (DNA) 和轉錄組 (RNA)。該公司對人類樣本進行了 WGS，用於研究項目，例如人口測序計劃。該公司的測試和分析被製藥公司用於轉化研究、生物標誌物發現、個性化癌症療法的開發。
公司簡介
公司代碼PSNL
公司名稱Personalis Inc
上市日期Jun 20, 2019
CEOMr. Christopher M. (Chris) Hall
員工數量229
證券類型Ordinary Share
年結日Jun 20
公司地址6600 Dumbarton Circle
城市FREMONT
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94555
電話16507521300
網址https://www.personalis.com/
公司代碼PSNL
上市日期Jun 20, 2019
CEOMr. Christopher M. (Chris) Hall
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Aaron Tachibana
Mr. Aaron Tachibana
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
163.21K
-0.39%
Dr. Richard Chen, M.D.
Dr. Richard Chen, M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
120.75K
-0.37%
Ms. Lonnie Shoff
Ms. Lonnie Shoff
Independent Director
Independent Director
20.63K
+99.99%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Chairman of the Board
Independent Chairman of the Board
13.51K
--
Mr. Stephen Moore
Mr. Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Senior Vice President, Chief Legal Officer, and Corporate Secretary
--
--
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Olivia K. Bloom, CPA
Ms. Olivia K. Bloom, CPA
Independent Director
Independent Director
--
--
Mr. A. Blaine Bowman
Mr. A. Blaine Bowman
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Hall
Mr. Christopher M. (Chris) Hall
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Aaron Tachibana
Mr. Aaron Tachibana
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
163.21K
-0.39%
Dr. Richard Chen, M.D.
Dr. Richard Chen, M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
120.75K
-0.37%
Ms. Lonnie Shoff
Ms. Lonnie Shoff
Independent Director
Independent Director
20.63K
+99.99%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Chairman of the Board
Independent Chairman of the Board
13.51K
--
Mr. Stephen Moore
Mr. Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Senior Vice President, Chief Legal Officer, and Corporate Secretary
--
--
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Independent Director
Independent Director
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
18.13M
88.00%
Others
2.47M
12.00%
業務
地區
暫無數據
股東統計
更新時間: 7月26日 週六
更新時間: 7月26日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Merck & Co Inc
15.90%
Tempus AI Inc
14.40%
Lightspeed Venture Partners
9.24%
ARK Investment Management LLC
8.05%
AIGH Capital Management, LLC.
3.15%
Other
49.26%
持股股東
持股股東
佔比
Merck & Co Inc
15.90%
Tempus AI Inc
14.40%
Lightspeed Venture Partners
9.24%
ARK Investment Management LLC
8.05%
AIGH Capital Management, LLC.
3.15%
Other
49.26%
股東類型
持股股東
佔比
Corporation
30.30%
Investment Advisor
17.42%
Investment Advisor/Hedge Fund
10.89%
Venture Capital
9.33%
Hedge Fund
3.49%
Private Equity
3.15%
Research Firm
1.79%
Individual Investor
1.18%
Pension Fund
0.67%
Other
21.77%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
223
69.16M
78.30%
+787.53K
2025Q1
223
76.78M
86.93%
+10.49M
2024Q4
213
73.54M
83.34%
+21.51M
2024Q3
203
51.51M
73.15%
+1.63M
2024Q2
208
30.80M
57.54%
-8.76M
2024Q1
264
31.11M
59.99%
-9.40M
2023Q4
271
31.05M
62.33%
-8.25M
2023Q3
297
34.10M
70.92%
-7.87M
2023Q2
312
35.53M
73.99%
-8.07M
2023Q1
327
36.62M
78.29%
-6.81M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Merck & Co Inc
14.04M
15.9%
--
--
Mar 31, 2025
Tempus AI Inc
12.72M
14.4%
+3.50M
+37.97%
Aug 16, 2024
Lightspeed Venture Partners
8.16M
9.24%
--
--
Mar 31, 2025
ARK Investment Management LLC
7.19M
8.14%
+412.76K
+6.09%
Mar 31, 2025
AIGH Capital Management, LLC.
2.98M
3.37%
+176.67K
+6.30%
Mar 31, 2025
abrdn Inc.
1.70M
1.93%
+1.41M
+472.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.70M
1.92%
+6.34K
+0.37%
Mar 31, 2025
The Vanguard Group, Inc.
1.29M
1.46%
-444.30K
-25.61%
Mar 31, 2025
Blue Water Life Science Advisors, LP.
1.18M
1.33%
+42.50K
+3.75%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.08M
1.22%
-20.66K
-1.87%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ARK Genomic Revolution ETF
4.48%
Invesco NASDAQ Future Gen 200 ETF
0.64%
Global X Genomics & Biotechnology ETF
0.52%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
查看更多
ARK Genomic Revolution ETF
佔比4.48%
Invesco NASDAQ Future Gen 200 ETF
佔比0.64%
Global X Genomics & Biotechnology ETF
佔比0.52%
iShares Micro-Cap ETF
佔比0.07%
ProShares Ultra Nasdaq Biotechnology
佔比0.06%
Invesco Nasdaq Biotechnology ETF
佔比0.06%
iShares Biotechnology ETF
佔比0.04%
Avantis US Small Cap Equity ETF
佔比0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.03%
iShares Russell 2000 Value ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
